Journal
ANNALS OF ONCOLOGY
Volume 21, Issue -, Pages 199-202Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdq452
Keywords
adjuvant treatment; lung cancer; predictive factor; prognostic factor
Categories
Ask authors/readers for more resources
Adjuvant platinum-based chemotherapy represents the standard of care in fit stage II and IIIA non-small-cell lung cancer patients after surgical resection. This review discusses current knowledge on molecular prognostic and predictive tumor features for benefit from adjuvant therapies with emphasis on ongoing clinical trials that prospectively assess the biomarker utility. Until the results of these trials are available, use of these markers is not recommended in routine clinical care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available